Skip to content
2000
Volume 28, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these patients. Plant- based compounds could be a potential option to treat KRAS-mutated NSCLC. These compounds are reported to be effective against the KRAS-linked up-stream and downstream signaling pathways that are directly or indirectly linked with cell proliferation, division, and apoptosis. Additionally, plant phytochemicals also suppressed different cell cycle phases of KRAS-mutant NSCLC cells. Furthermore, phytochemicals have a wider therapeutic index compared to chemotherapeutic drugs. Therefore, phytochemicals could benefit NSCLC patients as sole agents or as a combination therapy with approved chemotherapies. The current review aims to summarize the potential benefit of natural compounds in KRAS-mutant NSCLC.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867328666210301105856
2021-12-01
2025-01-10
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867328666210301105856
Loading

  • Article Type:
    Review Article
Keyword(s): and apoptosis; cell cycle; cell signaling; KRAS; NSCLC; phytochemicals
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test